RxDoctor Payments Data

Hardik Mehta, MD

Cardiovascular Disease · Huntersville, NCNPI 1619297595

Payments from drug & device makers

$3,611in general payments, 2019–2025

Across 175 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$523
  • Pfizer$467
  • Heartflow, Inc.$358
  • Johnson & Johnson$335
  • Novartis$320
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$271
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,611100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,611 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$166,832
Medicare patients
1,145
Services billed
3,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban459$509,696
VyndamaxTafamidis20$429,793
VyndaqelTafamidis Meglumine11$246,892
EntrestoSacubitril/Valsartan183$235,344
XareltoRivaroxaban183$203,585
JardianceEmpagliflozin152$159,727
Repatha SureclickEvolocumab77$60,913
FarxigaDapagliflozin Propanediol22$26,827
Praluent PenAlirocumab40$22,704
MultaqDronedarone Hcl15$17,489
Repatha SyringeEvolocumab26$17,077
Metoprolol Succinate850$9,885
Atorvastatin Calcium596$4,508
Rosuvastatin Calcium458$4,390
Flecainide Acetate116$3,928

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax, Vyndaqel$467$1,186,380490 claims
NovartisEntresto$320$235,344183 claims
Johnson & JohnsonXarelto$335$203,585183 claims
Boehringer IngelheimJardiance$131$159,727152 claims
AstraZenecaFarxiga$190$26,82722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →